Port wine stain are a congenital, progressive vascular malformation of human skin. The
pulsed dye laser is approved by the Food and Drug Administration for the treatment of
choice. However, the degree of port wine stain blanching seen following pulsed dye laser
treatment remains variable and unpredictable. If the ultimate standard required is complete
lesion blanching, the average success rate is below 10%, even after undergoing numerous
pulsed dye laser treatments. Moreover, less than 50% of patients achieve 50% fading of their
Port wine stain in response to pulsed dye laser therapy.
The researchers' specific aim is to determine whether the use of the pulsed dye laser
operating at a wavelength of 577 nm will improve therapeutic outcome as compared to a pulsed
dye laser operating at 595 nm.
The researcher can treat port wine stain treated using a pulsed dye laser operating at a
wavelength of 577 nm and the other half at a wavelength of 595 nm. The researcher can
determine that the 577 nm pulsed dye laser improved port wine stain blanching responses more
than the areas treated with 595 nm.
The degree of port wine stain blanching which will determine by visible reflectance
spectroscopy skin imaging device measurements. Post-treatment blanching responses can
compare with pre-treatment measurements of port wine stain fractional blood volume.
- Port Wine Stain suitable for comparison testing
- Age > 6 months of age; minor will be accompanied in the room by parents or guardians
during laser treatment
- Apparent good health as documented by medical history
- Ability to understand and carry out subject instructions
- History of photodermatoses or skin cancer
- Any therapy within the previous two months to the proposed Port Wine Stain treatment
- Inability to understand and carry out instructions
John S Nelson, M.D., Ph.D.
Beckman Laser Institute University of California Irvine